InflaRx CMD 2026
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Ladies and gentlemen, good morning and thank you for standing by. Thank you for joining the InflaRx Capital Markets event to discuss the evolving treatment landscape and unmet need in AAV, as well as our development strategy for izicopan in AAV and other renal indications. During today's presentation, all participants will be in a listen-only mode. A couple things to note here. First, that today's call is being recorded. Also, as usual, please take note of the disclaimers in our deck, which discusses the nature of our forward-looking statements. We will hear from a few different folks today that Niels will introduce in a bit. After that, we will go to a Q&A session where you can ask questions either through the side panel, written, or audio.
Also note, if you are accessing the call now, you need to really be logged in online to ask these questions, not via telephone. With that, I'd like to turn the call over to Niels Riedemann, CEO and founder of InflaRx. Niels, please go ahead. Thank you so much, John.
Welcome everyone to our Capital Markets Day. Good morning and good afternoon to all the listeners. We're really happy to have you for a very exciting session here today. I would like to first welcome also two world-class experts that we feel very lucky to have with us today on the call. Professor Jörg Köhl, who's one of the most accomplished research scientists in the area of complement, particularly C5a receptor, who will talk about the science behind ANCA vasculitis and the role of the C5a receptor and C5a in this disease. So, it's really great to have Dr. Köhl with us. Then Dr. Peter Merkel, professor of medicine and chief of rheumatology at UPenn, one of the KOLs, key opinion leaders, in the world of ANCA vasculitis clinical research.
So really, really happy to have you with us and supporting this sessions here, and also our development with your advice. With me on the call, my teammates, Dr. Gabriela Alperovich, who just joined the team as senior vice president and global head of clinical development. Gabriela will be available for Q&A. She's a trained nephrologist and extremely experienced in the renal disease development space. Of course, Tom Taapken, our chief financial officer, will be giving you some insights into external market research we very recently conducted. Next slide, please. We want to talk about avacopan today. The slide is not advancing. Could you advance to the next one, please? Thank you. We really want to talk about izicopan, our small oral C5a receptor antagonist, which we believe is really a triple threat for a potential best-in-class agent.
We are saying that because this drug has a very fast onset and a very high exposure, with a potential for better efficacy. We have really within one week, a target therapeutic exposure reach, what we believe is target. We will go into this here later in the presentation, but really also flagging that we have a very good control over the signal and in vivo head-to-head data with a marketed comparator where we show a clear increase, almost double the efficacy in that animal model in hamsters. We have no safety signals of concern so far. We have really low metabolite formation, 100-fold lower than the marketed comparator in the GSH trapping assay, especially in the early phase. That really entails we are not a time-dependent liver detoxifying enzyme CYP3A4/5 inhibitor.
That is very important for us, and we have, as of today, 197 subjects dosed with no safety signals of concern. We also have the potential for better convenience here. Clearly lowered pill burden is what we believe we may achieve. We have a threefold increased drug strength, and that really allows us for less dosing. On top of it, because we are not a CYP3A4 inhibitor, we may not have the same drug-drug interaction concerns, which may also have implications later. Next slide, please. Today's takeaways upfront, we are really excited about the market opportunity. We just did external market research that indicates really a very nice $1.5 billion-$2 billion peak sales potential scenario in ANCA-associated vasculitis. Our development strategy here is prime for generating differentiated efficacy and safety data. For that, we want to do two trials here.
One, as recently announced, a placebo-controlled study in patients with renal vasculitis, i.e., renal involvement, which is a group that is most commonly affected organ is the kidney. So it is really something that we are honing in on and really looking for different efficacy signals, particularly in the kidney space. Then the second one that we just recently added, an open-label study in all comers to demonstrate the ability to replace corticosteroids. So a slightly different patient population with a slightly different goal here to excite the physicians and also patients about the outlook to have less steroid use in this disease. We also want to do a study in AAVAS, which is already in the making, where we believe we may have initial first data maybe already in 2027. This is exciting. We will show you some details later.
Then also in a basket study where we currently start with IgAN and rapidly progressive IgAN, and potential others that are still in the discussion. This is also expected to start and have initial readouts maybe in 2028. We do want to flag there is a phase III study ongoing with our vilobelimab cell line-derived anti-C5a monoclonal antibody BDB-001 from our license partner in China that is expected to have data in 2028, here second half 2028. This is a large ANCA vasculitis trial in China where patients do not receive any corticosteroids, and we will be excited to see these data, of course, as well. Just want to end with saying we have a strong IP position. This is all in-house owned with izicopan and a strong balance sheet of EUR 153.3 million, that is, with a cash runway through to 2029. Next slide, please. So without further ado, we are excited to hear about the science behind ANCA vasculitis, and I turn this over to Professor Jörg Köhl, who is, as I mentioned, one of the key experts in the world in that.
We are very excited to have you, Dr. Köhl, and please, the floor is yours.
Yeah. So thank you very much, Niels. I am really delighted to give you today my perspective on the role of C5a receptor, and also targeting C5a receptor in AAV. Can I have the next slide, please? So before I go into the different pathways, just very, very briefly, because you will hear about this later, more from Professor Merkel, we are talking today about ANCA-associated vasculitis as a group of rare systemic small vessel diseases, where in the center are anti-neutrophilic cytoplasmic antibodies that target proteinase 3 on the one hand, myeloperoxidase on the other. And these ANCA activate neutrophils, and the prime neutrophils promote eventually endothelial injury and organ inflammation. The disease comes in different flavors. There are three main clinical types, GPA, MPA, and EGPA, where you find the different ANCAs. And the target organs are mainly the kidney and the lungs.
And I will talk about today from about many preclinical models where the target organ is the kidney. Next slide, please. So, diving directly into the pathways that drive the pathogenesis of this disease. It starts frequently with an infectious stimulus that can activate dendritic cells, that you see in the upper part of the slide. And this drives Th17 responses, and this IL-17 then activates macrophages to produce cytokines such as TNF and IL-1 beta. And this is important to prime neutrophils because this priming means that the two autoantigens, MPO and PR3, make their way to the surface, and are now exposed so that ANCAs can bind there. On the other hand, the infectious agents activate the complement system, and I will come to this in a minute. And this is also an important trigger for priming of neutrophils.
Once the neutrophils are activated, the Fc gamma receptors then drive excessive activation of the neutrophils with release of reactive oxygen metabolites, lytic enzyme, and there is also formation of NETs. Those together then drive the damage of the vascular endothelial cells. And the neutrophil is also important with regard to the B cell response because it is secreting, after activation, BAFF, an important survival factor of B cells, which is then critical to maintain the B cell response and those germinal center that produce the B cells that produce the ANCAs. Next slide, please. So going directly into the role of complement. And I want to show you today is that complement is involved in all different parts of the disease pathogenesis, priming, neutrophil activation with regard to ROS release, but also NET formation, and finally, also in the B cell response, which may surprise you. Next slide. I am showing you today evidence from preclinical models, and whenever I talk about preclinical mouse models, you will see a mouse icon on the left, or when I am talking about human studies, you would see an icon for human.
The evidence from the animal models comes from an MPO-induced AAV model, where, next please, the authors, back in 2007, compared wild type versus C5-deficient mice. After induction and after administration of MPO, the mice developed within a few days crescent glomerulonephritis with albuminuria, and leukocyturia, and hematuria, but also with crescentic necrotic glomeruli, as you can see in the middle. The C5-deficient animals, they were almost completely protected. Next. In parallel, several groups looked into patients suffering from AAV, and as you can see there, from immunohistochemical analysis, there is also deposition of C3 fragments such as Bb and C3d in the glomeruli in the upper part.
Not only there, but also in the small vessels, in the endothelial cells. As you may notice on the very right, there is also some deposition of C5b to 9, so of the terminal complement complex, suggesting that there may be also a role for this part, and I will come back to this in a minute. Next. The next question was then downstream of C5, which is cleaved into C5a and C5b. Is it the interaction with the C5a receptors that is critical, or is it more the terminal pathway?
In a study that was published back in 2009, it was demonstrated that in comparison to a wild-type mouse, which shows a strong damage in the glomeruli, that C5a receptor-deficient mice are almost completely protected. Also, you can see the heavily affected glomeruli in the middle, the wild-type mice, and very much preserved and looking almost healthy in the C5a receptor-deficient mice. You also can notice is that you see a massive influx of neutrophils under G, which is almost completely absent in F, in the C5a receptor-deficient mice. Next. In a more recent study published this year, in a huge cohort of AAV patients, it was shown that when you look into the kidneys and you do a transcriptomic analysis, what you notice is that in these kidneys, there is massive upregulation, as you can see in this volcano plot, complement components, complement regulators, but also on the very top, the C5a receptor 1.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
12 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
